the aid library

LIST OPTIONS

Filter

2856

Sort by:

Direction:

Download (2395)

View PDF (2348)

The Camp Managment Toolkit
recommended

Birkeland,N.M.; G.L. Forselv, V. Vogel, et al. NRCThe Camp Management Project (CMP) (2015) C1

Applicable to both IDP and refugee scenarios, the Toolkit incorporates a wide range of relevant information on managing displaced populations living in communal settings (collective centres, spontaneous sites, established camps, etc.). Large scale displacements caused by recent conflict and natural ... more

Download (543)

View PDF (1165)

Antimicrobial resistance and causes of non-prudent use of antibiotics in human medicine in the EU

European Commission (2017) C1

Antimicrobial resistance (AMR) is an increasing worldwide public health problem with important implications for the European Union (EU). When antibiotics become ineffective, bacterial infections lead to increased morbidity, use of healthcare, mortality and cost. Globally, estimates suggest that ... more

Download (175)

View PDF (248)

After emergency is over: Post-traumatic stress disorder in children and youth

Emergency Medical Services for Children EMSC (2019) C1

After a frightening or distressing experience (any kind of injury, a physical or sexual assault, car crash, fire, or other natural disaster), a child or teen may suffer psychological stress in addition to any physical injuries. When these reactions last for more than a month and are strong enough ... more

Download (519)

View PDF (682)

Money and Mosquitoes: The Economics of Malaria in an Age of declining Aid

Eric Maskin, Célestin Monga, Josselin Thuilliez and others African Development Bank (2018) C1

(African Development Bank policy research document 1)
The report examines financing in the battle against malaria, focusing on the role of foreign aid. It analyzes whether or not a disease such as malaria can be controlled or eliminated in Africa without health aid. It also presents a theoretic... more

Download (84)

View PDF (653)

Q&A: Antibiotic resistance: where does it come from and what can we do about it?

Wright G.D. BMC Biology (2010) C2

Historically, the discovery of the sulfa drugs in the 1930s and the subsequent development of penicillin during World War II ushered in a new era in the treatment of infectious diseases. Infections that were common causes of death and disease in the pre-... more

Download (121)

View PDF (180)

COVID-19 Nepal: Preparedness and Response Plan

UN Country Team in Nepal (2020) CC

The COVID-19 pandemic is having far reaching impacts, well beyond the health crisis and needs, with the most severe impacts experienced in the poorest countries and those most vulnerable to humanitarian crises including natural disasters, such as Nepal.

Download (97)

View PDF (141)

Global Humanitarian Response Plan COVID-19 Progress Report: Final Progress Report 22 February 2021

Office for the Coordination of Humanitarian Affairs OCHA (2021) C1

2020 was a year like no other. Amidst on-going humanitarian crises, largely fuelled by conflict and violence but also driven by the effects of climate change – such as the largest locust infestation in a generation – the world had to contend with a global pandemic. In less than one year (March-D... more

Download (141)

View PDF (145)

Migration health: 2019 activities overview - Leave no migrant behind

International Organization for Migration IOM (2020) C1

Every year, nearly 250 million people move across borders temporarily or permanently for a job opportunity, studying, to flee a crisis back home, or for other reasons. Another 750 million move for similar reasons within the borders of their countries. With the understanding that human mobility affec... more

Download (154)

View PDF (171)

Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection
recommended

World Health Organization WHO (2021) C_WHO

15 July 2021. This report describes the demographics, clinical presentation, clinical outcomes, and risk factors among people living with HIV (PLHIV) who have been hospitalized for suspected or confirmed COVID-19. The specific objectives of the analysis were to: describe the clinical char... more

Download (201)

View PDF (252)

Interactive Atlas of Leishmaniasis in the Americas: Clinical Aspects and Differential Diagnosis

Pan American Health Organisation PAHO (2021) C_WHO

In the Region of the Americas, the leishmaniases are a group of diseases caused by various species of Leishmania, which cause a set of clinical syndromes in infected humans that can involve the skin, mucosa, and visceral organs. The spectrum of clinical disease is varied and depends on the interacti... more

Download (386)

View PDF (456)

South African MATERNAL, PERINATAL, and NEONATAL Health Policy

National Department of Health (NDoH) South Africa NDoH South Africa (2021) CC

As a lower-middle-income country (LMIC), South Africa (SA) bears the burden of maternal and neonatal mortality similar to other sub- Saharan African countries. According to the Saving Mothers Report 2017/19, there has been a progressive and sustained reduction in institutional maternal mortality... more

Download (173)

View PDF (205)

Scoping review of interventions to maintain essential services for maternal, newborn, child and adolescent health and older people during disruptive events

World Health Organization WHO (2021) C_WHO

To support countries in adapting their response to different COVID-19 scenarios, the World Health Organization (WHO) Department of Maternal, Newborn, Child and Adolescent Health and Ageing commissioned this scoping review of published and grey literature. The objective was to identify interventions... more

Download (140)

View PDF (169)

Sixteenth meeting of the Strategic and Technical Advisory Group for Neglected Tropical Diseases (STAG-NTDs)

World Health Organisation (WHO) (2023) C_WHO

The sixteenth meeting of the Strategic and Technical Advisory Group for Neglected Tropical Diseases (STAG-NTD) was held as a hybrid meeting, 27–28 September 2022. Dr Ren Minghui, Assistant Director-General, Universal Health Coverage/Communicable and Noncommunicable Diseases, welcomed participan... more

Download (114)

View PDF (132)

WHO Timor-Leste Country Cooperation Strategy: 2021-2025

World Health Organisation (WHO) (2023) C_WHO

In the last decade, Timor-Leste has made remarkable progress in strengthening its health system and improving the health status of its population. This has resulted in an increased life expectancy, and the achievement of Millennium Development Goals such as a reduction in infant and under-five morta... more

Download (112)

View PDF (581)

Visceral leishmaniasis: a global overview

Wamai, R.; Khan, J.; McGloin, J.; Ziaggi, G. Jornal of Global Health Science (2020) CC

A group of enzootic and zoonotic protozoan infections, the leishmaniases constitute among the most severely neglected tropical diseases (NTDs) and are found in all continents except Oceania. Representing the most common infectious diseases, NTDs comprise an open-ended list of some 20 parasitic, bact... more

Download (197)

View PDF (152)

Global Accelerated Action for the Health of Adolescents (AA-HA!): guidance to support country implementation, second edition.

World Health Organization WHO (2023) C_WHO

The World Health Organization (WHO) is releasing the second edition of its Global Accelerated Action for the Health of Adolescents (AA-HA!) guidance. The document aims to equip governments to respond to the health and well-being challenges, opportunities and needs of adolescents. The guidance pro... more

Download (139)

View PDF (122)

Guidance for country validation of viral hepatitis elimination and path to elimination

World Health Organization WHO (2023) C_WHO

Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis B and C impact targets to demonstrate elimination, whilst highlighting challenges caused by hig... more

Download (245)

View PDF (330)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (140)

View PDF (192)

Lao People’s Democratic Republic-WHO Country Cooperation Strategy 2024–2028

World Health Organization WHO (2023) C_WHO

This country cooperation strategy (CCS) outlines how the World Health Organization (WHO) will work with the Lao People’s Democratic Republic over the next five years (2024–2028), supporting the implementation of the five-year health sector development plans and the Health Sector Reform Strategy ...2021–2030 to attain the Sustainable Development Goals (SDGs) by 2030. The Lao People’s Democratic Republic experienced substantial economic growth in the 30 years prior to the coronavirus disease (COVID-19) pandemic, contributing to reduced poverty and significant progress toward the SDGs. However, the COVID-19 pandemic brought this development to a halt. It was anticipated that the COVID-19 recovery and the tremendous population growth in recent years would provide opportunities for a shift toward more sustainable and inclusive development in the years ahead. In 2023, however, the contrary was the case. Rural residents, including many ethnic minorities, continued to face marginalization because of limited access to education, health care and economic opportunities. Despite the challenges of COVID-19 and other disease outbreaks, the country has made significant improvements in health. Nonetheless, progress has been uneven and not everyone has benefited from these achievements. In the mountainous region, many people lack access to quality health care because of the unequal distribution of well-trained health-care workers. Preventable deaths due to poor-quality health care for children and newborns, infants and mothers remain a concern, as do communicable diseases such as sexually transmitted infections and tuberculosis. The increasing burden of noncommunicable diseases and the health impact of worsening climate change further heighten the need for strengthened and resilient health systems, which are at risk due to an underfunded health sector and weak economy. This CCS aims to address remaining and future challenges as well as health needs while creating an impact that is sustainable. It identifies three strategic priorities and nine deliverables (Table 1) to support the attainment of the national vision of Health for all by all, as articulated in the 9th Health Sector Development Plan 2021–2025. It contributes to the country’s goals to achieve universal health coverage, graduate from least developed country status by 2026 and attain SDGs by 2030. more

Download (150)

View PDF (102)

Global Malaria Programme operational strategy 2024–2030
recommended

World Health Organization WHO (2024) C_WHO

Ahead of World Malaria Day, the WHO Global Malaria Programme published a new operational strategy outlining its priorities and key activities up to 2030 to help change the trajectory of malaria trends, with a view to achieving the global malaria targets. The strategy outlines 4 strategic objectives ... more

The Camp Managment Toolkit recommended

Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection recommended

Global Malaria Programme operational strategy 2024–2030 recommended

The Camp Managment Toolkit
recommended

Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection
recommended

Global Malaria Programme operational strategy 2024–2030
recommended